Browse Category

Biotechnology 4 May 2026 - 20 May 2026

Iovance shares surge 43% as Amtagvi revenue highlights manufacturing turning point
Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Inc. shares jumped in heavy U.S. trading on Tuesday after the molecular diagnostics company said it had completed a strategy for a possible Ebola assay tied to the Bundibugyo virus outbreak in the Democratic Republic of Congo and Uganda. The stock was recently up 51% at $2.07, after touching $2.73, on volume above 94 million shares; the iShares Russell 2000 exchange-traded fund, a small-cap stock basket, was down about 1.2%.
19 May 2026
···
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio shares were active before the Nasdaq bell on Monday after the company said five U.S. patents will protect its Anktiva-plus-BCG bladder cancer treatment into at least 2035. This statement followed Friday’s announcement of an exclusive U.S. supply deal with Japan BCG Laboratory. The stock last traded at $7.97, unchanged from Friday’s close, when it slipped 2.2% on volume of 11.3 million shares.
18 May 2026
··
WORK Medical Technology Group Stock Triples After AI BioToken Deal — What Investors Need to Know

WORK Medical Technology Group Stock Triples After AI BioToken Deal — What Investors Need to Know

Shares of WORK Medical Technology Group LTD swung sharply in Tuesday’s premarket, after the U.S.-listed stock soared more than threefold on Monday. The move tracked news of an AI tie-up with Shanghai Novabioplus Biotechnology Co. The two firms aim to create medical models leveraging protein data and what WORK calls “BioTokens”—digital assets representing biological data.
12 May 2026
···
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Ernexa Therapeutics Inc. reported Wednesday that its lead cell therapy, ERNA-101, paired with PD-1 blockade, wiped out tumors completely and delivered 100% long-term survival in preclinical ovarian cancer studies. “Complete tumor eradication and durable survival,” is how Chief Scientific Officer Robert H. Pierce summed up the results. Chief Executive Sanjeev Luther called the data “beyond expectations.”
6 May 2026
···
Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Late Tuesday, Avalo Therapeutics Inc. locked in a $375 million public offering—just hours after rolling out upbeat Phase 2 results for abdakibart. Riding the surge of interest tied to its hidradenitis suppurativa program, the company aims to fund its looming Phase 3 plans. Avalo is set to offer 19.73 million shares at $17.75 apiece, along with pre-funded warrants for another 1.4 million shares at $17.749 each. Closing is slated for May 7, pending standard closing conditions.
6 May 2026
··
Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Shares of Mirum Pharmaceuticals surged Monday, after the company announced its experimental therapy volixibat hit the primary endpoint in a Phase 2b study targeting primary sclerosing cholangitis, or PSC—a rare liver condition marked by scarring of the bile ducts and potential liver failure. The study zeroed in on cholestatic pruritus, the intense itching caused by impaired bile flow and notorious as one of PSC’s toughest symptoms.
4 May 2026
··
Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Inc. shares surged close to 16% Monday, after the Minneapolis-based biotech announced late Friday its lead drug candidate, gedatolisib, hit the primary endpoint in a late-stage breast cancer trial for patients with PIK3CA-mutant tumors. That news brought back attention to a July FDA decision and a planned cancer conference update in June for CELC stock.
4 May 2026
···
1 2 3 4 5 6 … 21
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Constellation Energy

NASDAQ: CEG 95 / 100
#2 BUY

AerCap

NYSE: AER 93 / 100
#3 BUY

Walt Disney

NYSE: DIS 92 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 90 / 100
#5 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.